Why the study?
Anticoagulants have been underused in elderly patients despite well-established benefits in NVAF, leaving a need for detailed information on clinical status and therapeutic challenges in this population.
No takes yet. Share an insight, caveat, or question.
Provides real-world outcomes data on elderly NVAF; leaves open optimal OAC strategies pending randomized confirmation.
Koretsune et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: